| | | | | | | 广东潮宏基实业股份有限公司 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 编制人：广东潮宏基实业股份有限公 | | | | | | | | | | | | | | | | | 司 | | | | | | | | | | | | | 单位：万元 | | | | | | | 占用方与上市 | | 上市公司核 | | 2025 年期初 | | | 2025 | 年 1-6 | 月 | 2025 年 | 1-6 | 月 | | 2025 6 年 | | 月末 | | | | | | | | | | | | | | | 非经营性资 | | | | | | | 占用累计发 | | | | | | | | | | 生 | | | | | | | 占用形 | | | | | | | | | | | | 资金占用方名称 | | 公司的关联关 | | 算的会计科 | 占用资金余 | | | | | | 占用资金 ...

| | | | | 翰博高新材料（合肥）股份有限公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 编制单位：翰博高新材料（合肥）股份有限公 | | | | | | | | | 司 | | | | | | | | | 单位：万元 | | | | | | | | | | | 占用方与上市公司的关联 | | 上市公司核算的会计科 | | 2025年1-6月占用累计发生金 | 2025 | | 年1-6月占用资金 | 2025年1-6月偿还累计 | 2025年6月末占用 | | | | | | | 非经营性资金占用 | | 资金占用方名称 | | | 2025年初占用资金余 | | | | 额 | | | | 占用形成原因 | 占用性质 | | | | | | 关系 | 目 | | | 额(不含利息) 的利息(如有) | 发生 | | 金额 资金余额 | | | | | | | | | 控股股东、实际控制人及其附属企 业 | | | | | | | | | 小计 | — | — | | | | | | | — | - | - | - | - ...

168.57 往来款 来 管理有限 公司 其他关联方及其附 属企业 | 编制单位：深圳翰宇药业股份有限公 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 司 | | | | | | | | 单位：万元 | | | | | 资金占 | | 占用方与上 | | 上市公司核 | 2025 年期 | | 2025 | 年度占 | 2025 | 年度偿 | 2025 年 | | 期末 | | | | | | | | | | | | | | | | | | 用累计发生 | | | | | 占用形 | | | 非经营性资金占用 | | 用方名 | | 市公司的关 | 算的会计科 | 初占用资 | | | 用资金的利 | | 还累计发生 | | 占用资金余 | | | | 占用性质 | | | | | | | | | | | | | | 金额（不含利 | | | | | | 成原因 | | 称 | | 联关系 | 目 | 金余额 | | | 息（如有） | | 金额 | 额 ...

一品红药业集团股份有限公司 按照《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》(证监会公告[2022]26 号文）及其他相关规定，公 司 2025 年半年度非经营性资金占用及其他关联资金往来情况如下表所示： 上市公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | 单位：元 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上 | 上市公司核 | | 2025 年半年度占 | | 2025 年半年度 | | | | | 非经营性资 | 资金占用方名称 | | 市公司的关 | 2025 年半年度期 算的会计科 | | 年度占用 用累计发生金额 | | 2025 年半年度期 偿还累计发生 | 占用形 | 占 | | 用性质 | | | | | | | | | | | | 金占用 | | | | 初占用资金余额 | | 资金的利 | | 末占用资金余额 | 成原因 | | | | | 联关系 | 目 | | （不含利息） | ...

Group 1 - The document reports on the financial status of Wuxi Xinan Technology Co., Ltd. as of June 30, 2025, indicating that there are no non-operating fund occupations or related party transactions recorded [1][1][1] - The total amount of funds occupied and related party transactions is reported as zero, suggesting a clean financial slate with no outstanding obligations or liabilities in these areas [1][1][1] - The document includes details about the legal representatives and accounting personnel, confirming the governance structure of the company [1][1][1] Group 2 - The report emphasizes that there are no financial interactions with controlling shareholders, actual controllers, or their affiliated enterprises, indicating a lack of financial entanglements [1][1][1] - The absence of any recorded amounts for other related parties further reinforces the company's straightforward financial dealings [1][1][1] - The document serves as a formal financial statement, ensuring transparency and compliance with regulatory requirements [1][1][1]

经贸有限公司 及其附属企业 其他关联方及其附 属企业 总计 - - - 0.20 0.10 0.30 - | 编制单位：哈尔滨敷尔佳科技股份有限公 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 司 | | | | | | | | | | 单位：万元 | | | | | 占用方与上 | 上市公司核 | 2025 | 2025 年期 | 年 | 1-6 月占 | 2025 | 1-6 年 | 2025 月 | 1- 年 | | 6 2025 6 年 | 月 | | | | | | | | | | | | 资金占用方 | | | | | | | | | | | | | 占用形 | | | | | | | | | | | | | 非经营性资金占用 | | | 市公司的关 | 算的会计科 | 初占用资 | | 用累计发生金额 | | 占用资金的利 | | 月偿还 | | 累计 30 日期末占 | | | | | 占用性质 | | | | | | | | 名称 | | ...

飞天诚信科技股份有限公司 关于公司 2025 上半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市 | 上市公司核 | | 度占用累计 | | 2025 | 2025 半年度 | | 半年度 | | | | | | | | | | 非经营性资金占 | | | | 期初占 | | 度占用资 | | | | 占用形成 | 资金占用方名称 | | 公司的关联关 | 算的会计科 | | 发生金额 | | 偿还累计发 | | 期末占用资 | | 占用性质 | | | | | | | | 用 | | | 用资金 | | | 金的利息 | | 原因 | | | | 系 目 | | （不含利 | | | 生金额 | 金余额 | | | | | 余额 | | （如有） | | | | | | | | | 息） | | | | | | 控股股东、实际控 | | | | | | | | | | 制人及其附属企 | | | | | | | | | ...

Summary of Key Points Core Viewpoint - The documents provide detailed financial data regarding the accounts receivable and other financial interactions of Shandong Linuo Pharmaceutical Packaging Co., Ltd. with its related parties, highlighting significant amounts in both operating and non-operating transactions. Group 1: Accounts Receivable - The total accounts receivable from various related parties includes significant amounts such as 9.80 million from Shandong Hongjitang Pharmaceutical Group and 2.56 million from Hongjitang Bianque Chinese Medicine Pharmacy [1][2] - Other notable accounts receivable include 18.21 million from Linuo International Trade Co., Ltd. and 13.60 million from another related entity [2][3] - The company has a total of 240.25 million in accounts receivable, with a breakdown showing substantial amounts owed by various subsidiaries and related parties [3] Group 2: Financial Transactions - The documents indicate that there are non-operating fund usages amounting to significant figures, although specific amounts are not detailed in the provided text [1] - The financial interactions also include prepayments and other receivables, with 169.18 million noted for prepayments to a related gas company [3] - The total financial transactions involving related parties reflect a complex web of inter-company dealings, emphasizing the importance of monitoring these relationships for financial health [3]

Group 1 - The company held its first special meeting of the sixth board of independent directors on August 8, 2025, with all four independent directors participating in the vote [1] - The meeting reviewed and approved the proposal regarding the non-operating fund occupation and other related fund transactions for the first half of 2025, confirming that all transactions with related parties were normal and did not harm the interests of the company or minority shareholders [1] - The voting results showed unanimous approval with 4 votes in favor, 0 against, and 0 abstentions [1]

| 陕西汉江药业集团股份有限公司 | | | | 子公司 | 应收股利 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 7,088.26 | - | - | | 7,088.26 | - | 分配股利 | 非经营性往来 | | | | 重庆华邦制药有限公司 | | | | 子公司 | 应收股利 | | 40,036.98 | 8,025.93 | - | | 48,062.91 | - | 分配股利 | 非经营性往来 | | | | | | | | 其他关联方及其附属 | 重庆松山医院 | | | | 其他关联方 | 应收账款 | 25,624.91 | | | | 12,194.67 | | 2,904.75 | | | 34,914.83 销售及租赁等业务 | 经营性往来 | | | | | 企业 | 重庆松山医院 | | | 其他关联方 | 其他应收款 | | 45,150.61 | 14,126.00 | | | 751.67 | 18,226.00 | 41,802.28 | | 借款 非经营性往来 ...